New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.

Autores de IIS La Fe

• Vicente Enrique Villanueva Haba

  Autor

Participantes ajenos a IIS La Fe

• Carreño-Martínez M
• Gil Nagel-Rein A
• López-González FJ

Abstract

Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are two serious epileptic syndromes with paediatric onset which are refractory to therapy and are associated with an important increase in mortality rates and comorbidities compared to the general population. These pathologies have a strong impact on the lives of patients and their families, because they undergo multiple pharmacological therapies (many of them without specific indication), with frequent changes due to poor efficacy and associated adverse effects. The specialists who care for these patients highlight unmet needs and the lack of specific, safe and effective treatments for better management of the syndrome.

Keywords

• Antiepileptic; Cannabidiol; Dravet syndrome; Lennox-Gastaut syndrome; Refractory epilepsy; Severe epilepsy